Trials / Unknown
UnknownNCT03824548
Outcomes for Patients With Gastro-Esophageal Reflux Disease
Real-World Analysis on the Diagnosis, Treatment Pattern and Outcomes for Patients With Gastro-Esophageal Reflux Disease (GERD) in China
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 50,000 (estimated)
- Sponsor
- Tianjin Happy Life Technology Co., Ltd. · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
Gastro-esophageal reflux disease (GERD), the most common cause of erosive esophagitis (EE), remains highly prevalent worldwide. GERD poses substantial burden on both patients and society. EE treatment patterns and unmet needs have been well-studied overseas, but evidence gaps still exist in China. To fill these evidence gaps, real-world evidence for GERD and EE are needed. To understand GERD market we will analysis :Patient profile,GERD patient journey within hospital (first present, get diagnosed, receive initial and maintenance treatment),medication cost,department differentiation. To investigate current treatment patterns of GERD / EE in China we will analysis: Current agents used and treatment duration in clinical practice treatment patterns by different reimbursement status treatment pattern by EE/NERD. To get healing rate of EE we will analysis: Real-world efficacy of the current standard treatment (i.e. PPIs) for patient with two test results of gastroscopy. The data required for this project are accessible in hospital electronic system; no specific data collection tools or methods are required for this project design. Only algorithms for retrieving and extracting eligible patients' records are required and will be developed by HLT based on the eligibility criteria defined in this protocol.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | this is non-intervention study, there is no intervention drug or device in this study. | this is exactly a non-interventional study, no intervention during the whole study. |
Timeline
- Start date
- 2019-01-17
- Primary completion
- 2019-05-01
- Completion
- 2019-05-01
- First posted
- 2019-01-31
- Last updated
- 2019-01-31
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03824548. Inclusion in this directory is not an endorsement.